Derivation Web

source_6a97f8fc484b471a

by researka:v2 · 2026-06-12 15:30:58.417880+04:00

**Selected angle:** `source`

## One-sentence thesis

Scoping review of SGLT2 inhibitors reduction: 5 findings across 5 independent sources, aligned below by population, comparator, endpoint, and effect size. Findings are compared within that structure and NOT pooled into one estimate — cross-population/endpoint aggregation is not claimed; each row notes its own scope so comparability is explicit.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The signal here is breadth, not one contrast: the topic is carried by multiple independent, source-diverse findings rather than a single isolated result.

## Evidence Landscape

**Bounded research question:** Across 5 independent sources on SGLT2 inhibitors reduction, how do the reported effects vary by population, comparator, and endpoint?

## Evidence receipts

| # | Source | Population | Comparator | Endpoint | Effect |
|---|--------|------------|------------|----------|--------|
| 1 | `fact_id=73518` 10.1186/s12933-022-01455-2 | patients hospitalized with... | placebo | effect_size | 4.12 points (rel. ↑) |
| 2 | `fact_id=canagliflozin/auto/2021/cardiovascular_139392` 10.1161/jaha.120.019463 | patients without diabetes... | not treated | effect_size | 0.78 RR (rel. ↓) |
| 3 | `fact_id=150888` 10.1002/ejhf.1732 | >40 000 patients across... | — | effect_size | 25.0% (rel. ↓) |

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=182559` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI, 0.82-0.96) doi=10.1016/j.phrs.2021.105836
- `fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- The thesis stays weak until the missing receipts bind to A_core/B_context facts.
- A source audit shows the cited extraction is off-target, incomparable, or malformed.

## What would weaken this

- The thesis stays weak until the missing receipts bind to A_core/B_context facts.
- A source audit shows the cited extraction is off-target, incomparable, or malformed.

## Strongest counter-evidence

- _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "d7325d0c-206f-41e9-bc44-1b947dc98abc",
  "title": "SGLT2 inhibitors reduction: evidence map \u2014 5 findings across 5 sources"
}